Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Simulations Plus, Inc. - Common Stock (NQ:SLP)

12.82 -0.20 (-1.54%)
Streaming Delayed Price Updated: 1:44 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Simulations Plus, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
From Pomerantz LLP
Via GlobeNewswire
SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design
From Simulations Plus, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
From Pomerantz LLP
Via GlobeNewswire
SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation – SLP
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
From Pomerantz LLP
Via GlobeNewswire
Simulations Plus Invests in Clinical Development Technology Company Nurocor
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor® 13
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases DILIsym® 11
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the BTIG Digital Health Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Stephens Annual Investment Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
From Simulations Plus, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.